The DOI matches its Crossref record; 138 of the 140 references it cites were found in a registry or an index.
Non-motor symptoms of Parkinson's disease: diagnosis and management
Abstract
The clinical diagnosis of Parkinson's disease rests on the identification of the characteristics related to dopamine deficiency that are a consequence of degeneration of the substantia nigra pars compacta. However, non-dopaminergic and non-motor symptoms are sometimes present before diagnosis and almost inevitably emerge with disease progression. Indeed, non-motor symptoms dominate the clinical picture of advanced Parkinson's disease and contribute to severe disability, impaired quality of life, and shortened life expectancy. By contrast with the dopaminergic symptoms of the disease, for which treatment is available, non-motor symptoms are often poorly recognised and inadequately treated. However, attention is now being focused on the recognition and quantitation of non-motor symptoms, which will form the basis of improved treatments. Some non-motor symptoms, including depression, constipation, pain, genitourinary problems, and sleep disorders, can be improved with available treatments. Other non-motor symptoms can be more refractory and need the introduction of novel non-dopaminergic drugs. Inevitably, the development of treatments that can slow or prevent the progression of Parkinson's disease and its multicentric neurodegeneration provides the best hope of curing non-motor symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, non-motor symptoms dominate the clinical picture of PD”
From Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: The study protocol of a randomised pilot trial (2017) · cites this paper as [2]
In the citing paper
“and contribute to severe disability, impaired quality of life, and shortened life expectancy [2].”
From Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: The study protocol of a randomised pilot trial (2017) · cites this paper as [2]
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Unified Parkinson's Disease Rating Scale
(2012) · Springer eBooks · doi:10.1007/springerreference_184495 · Cited by 3,071
Parkinson, J. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.2.223 · Cited by 2,856
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop
Parent, A., & Hazrati, L.-N. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00007-c · Cited by 2,161
Research works printed but not linked: 7
- Chaudhuri, 2004, The holistic management of Parkinson's using a novel non-motor symptom scale and questionnaire, Adv Clin Neurosci Rehab, 4, 20
- Gulati, 2004, A clinical observational study of the pattern and occurrence of non-motor symptoms in Parkinson's disease ranging from early to advanced disease, Mov Disord, 19, S406
- Abbott, 2005, Excessive daytime sleepiness and the future risk of Parkinson's disease, Mov Disord, 20, S101
- Doder, 2000, Brain serotonin 5HT1A receptors in Parkinson's disease with and without depression measured by positron emission tomography with 11C-WAY 10635, Mov Disord, 15, 213
- Diederich, 2005, Repeated visual hallucinations in Parkisnon's disease as disturbed external/internal perceptions: focused review and a new integrative model, Mov Disord, 20, 130, 10.1002/mds.20308 · DOI
- Tyvaert, 2005, Sexual dysfunction and sub-thalamic stimulation in Parkinson's disease, Park Related Disord, 11, 116
- Isaacson, 2005, Non-motor symptoms frequently herald end-of-dose wearing off in Parkinson's disease, Mov Disord, 20, S52
Cited by
Sorted by citations
Items 401–500 of 1,008
Sensorimotor adaptation of voice fundamental frequency in Parkinson's disease
Abur, D., Lester‐Smith, R. A., Daliri, A., Lupiani, A. A., Guenther, F. H., & Stepp, C. E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191839 · Cited by 85
“…is difficult to circumvent in studies of PD, as there are a wide range of motor and non-motor symptoms seen in the clinical population of individuals with PD (Chaudhuri, Healy, & Schapira, 2006; Foltynie, Brayne, & Barker, 2002; Hughes, Daniel, Blankson, & Lees, 1993; van Rooden et al., 2010).”
Padhi, P., Worth, C., Zenitsky, G. D., Jin, H., Sambamurti, K., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.836605 · Cited by 84
PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease
Stocchi, F., Giorgi, L., Hunter, B. N., & Schapira, A. H. V. (2011) · Movement Disorders · doi:10.1002/mds.23498 · Cited by 79
Self-citationde Castro, A. A., Ghisoni, K., Latini, A., Quevedo, J., Tasca, C. I., & Prediger, R. D. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.01.016 · Cited by 82
Pierantozzi, M., Placidi, F., Liguori, C., Albanese, M., Imbriani, P., Marciani, M. G., Mercuri, N. B., Stanzione, P., & Stefani, A. (2016) · Sleep Medicine · doi:10.1016/j.sleep.2016.01.016 · Cited by 79
Duce, J. A., Wong, B. X. W., Durham, H., Devedjian, J.-C., Smith, D. P., & Devos, D. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0186-8 · Cited by 81
“Additive non-motor symptoms include cognitive deficits, sleep disturbances, anxiety, motivation disorders and mood disorders [2].”
Wolz, M., Hauschild, J., Fauser, M., Klingelhöfer, L., Reichmann, H., & Storch, A. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.05.011 · Cited by 78
Irritable bowel syndrome correlates with increased risk of Parkinson’s disease in Taiwan
Lai, S., Liao, K., Lin, C., & Sung, F. (2014) · European Journal of Epidemiology · doi:10.1007/s10654-014-9878-3 · Cited by 84
Dopaminergic Mechanisms Underlying Normal Variation in Trait Anxiety
Berry, A. S., White, R. L., Furman, D. J., Naskolnakorn, J. R., Shah, V. D., D’Esposito, M., & Jagust, W. J. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.2382-18.2019 · Cited by 83
“The direction of this relationship is consistent with observations in Parkinson’s disease in which the prevalence of comorbid anxiety is estimated to be as high as 40% (Richard et al., 1996), and often precedes the onset of motor symptoms (Chaudhuri et al., 2006).”
ResultThe Central Autonomic Network and Regulation of Bladder Function
Roy, H., & Green, A. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00535 · Cited by 80
“Common autonomic symptoms in Parkinson’s disease include orthostatic hypotension, swallowing difficulties, sweating, constipation, diarrhea, and urinary storage symptoms including frequency, urgency, and nocturia (Sakakibara et al., 2001; Chaudhuri et al., 2006; Jain, 2011).”
BackgroundTherapeutic Insights on Ferroptosis in Parkinson's disease
Thapa, K., Khan, H., Kanojia, N., Singh, T. G., Kaur, A., & Kaur, G. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175133 · Cited by 76
Understanding the dopaminergic deficits in Parkinson’s disease: Insights into disease heterogeneity
Lewis, S. J. G., & Barker, R. A. (2009) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2008.08.020 · Cited by 78
Parkinson’s disease mouse models in translational research
Antony, P. M. A., Diederich, N. J., & Balling, R. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9330-x · Cited by 84
“reduced cardiac [(123)I]metaiodobenzylguanidine (MIBG) uptake, and, possibly, reduced color discrimination (Chaudhuri et al. 2006; Fujishiro et al. 2008; Hawkes 2008; Katzenschlager and Lees 2004).”
BackgroundChen, S., Chan, P., Sun, S., Chen, H., Zhang, B., Le, W., Liu, C., Peng, G., Tang, B., Wang, L., et al. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0059-z · Cited by 77
“, hyposmia, rapid eye movement (REM) sleep behavior disorder, constipation and depression [3–6].”
Diffusion alterations associated with Parkinson's disease symptomatology: A review of the literature
Hall, J. M., Martens, K. A. E., Walton, C. C., O’Callaghan, C., Keller, P. E., Lewis, S. J. G., & Moustafa, A. A. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.09.026 · Cited by 79
What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis
Athauda, D. S., Maclagan, K., Budnik, N., Zampedri, L., Hibbert, S., Skene, S. S., Chowdhury, K., Avilés-Olmos, I., Limousin, P. D., & Foltynie, T. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181329 · Cited by 79
“appearance of motor deficits, while others such as cognitive impairment and autonomic dysfunction can come to dominate the clinical picture in advancing stages and influence the need for advanced care [1].”
Effects of Ropinirole on Nonmotor Symptoms of Parkinson Disease
Rektorová, I., Baláž, M., Svátová, J., Zárubová, K., Honig, I., Dostal, V., Sedláčková, S., Nestrašil, I., Mastík, J., Bareš, M., et al. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31815d25ce · Cited by 77
“Despite the emphasis on motor function, several studies have shown that the nonmotor symptoms of PD have greater significance than the motor symptoms when assessed in terms of quality-of-life measures, institutionalization rates, or health economics.(2) The Movement Disorders Society Task Force highlighted insufficien…”
BackgroundSynaptic proteins in CSF relate to Parkinson’s disease stage markers
Bereczki, E., Bogstedt, A., Höglund, K., Tsitsi, P., Brodin, L., Ballard, C., Svenningsson, P., & Aarsland, D. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0008-2 · Cited by 72
Esophageal dysfunction in different stages of Parkinson's disease
Suttrup, I., Suttrup, J., Suntrup‐Krueger, S., Siemer, M., Bauer, J., Hamacher, C., Oelenberg, S., Domagk, D., Dziewas, R., & Warnecke, T. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12915 · Cited by 80
Rotigotine Transdermal Patch: A Review in Parkinson’s Disease
Frampton, J. E. (2019) · CNS Drugs · doi:10.1007/s40263-019-00646-y · Cited by 76
Wang, Y., Shao, W.-B., Gao, L., Lu, J., Gu, H., Sun, L., Tan, Y. L., & Zhang, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116123 · Cited by 76
Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
Heinzel, S., Berg, D., Binder, S., Ebersbach, G., Hickstein, L., Herbst, H., Lorrain, M., Wellach, I., Maetzler, W., Petersen, G., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00500 · Cited by 75
Bento‐Pereira, C., & Dinkova‐Kostova, A. T. (2020) · Medicinal Research Reviews · doi:10.1002/med.21714 · Cited by 79
Winder‐Rhodes, S., Garcia-Reitboeck, P., Ban, M., Evans, J., Jacques, T. S., Kemppinen, A., Foltynie, T., Williams‐Gray, C. H., Chinnery, P. F., Hudson, G., et al. (2011) · Movement Disorders · doi:10.1002/mds.24029 · Cited by 75
“Parkinson’s disease (PD) is a common neurodegenerative disorder, characterized clinically by the triad of bradykinesia, rigidity, and tremor, alongside a wide range of nonmotor features.(1) The pathologic hallmark is loss of dopaminergic neurons from the substantia nigra pars compacta and the development of Lewy bodie…”
BackgroundMagnard, R., Vachez, Y. M., Carcenac, C., Krack, P., Olivier David, A., Savasta, M., Boulet, S., & Carnicella, S. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.17 · Cited by 75
Multidisciplinary care for people with Parkinson’s disease: the new kids on the block!
Radder, D. L. M., de Vries, N. M., Riksen, N. P., Diamond, S. J., Gross, D. R., Gold, D. R., Heesakkers, J. P. F. A., Henderson, E. J., Hommel, A. L. A. J., Lennaerts, H. H., et al. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1561285 · Cited by 75
“Parkinson’s disease (PD) is a chronic, multisystem neurological disorder with a complex and heterogeneous phenotype [1].”
BackgroundZarotti, N., Eccles, F. J. R., Foley, J. A., Paget, A., Gunn, S., Leroi, I., & Simpson, J. (2021) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1111/papt.12321 · Cited by 73
Developing dopaminergic cell therapy for Parkinson's disease—give up or move forward?
Lindvall, O. (2013) · Movement Disorders · doi:10.1002/mds.25378 · Cited by 78
Dance and Parkinson’s: A review and exploration of the role of cognitive representations of action
Bek, J., Arakaki, A. I., Lawrence, A., Sullivan, M., Ganapathy, G., & Poliakoff, E. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.023 · Cited by 81
Facile Impedimetric Analysis of Neuronal Exosome Markers in Parkinson’s Disease Diagnostics
Fu, Y., Jiang, C., Tofaris, G. K., & Davis, J. J. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c03092 · Cited by 74
Management of Sleep Disturbances in Parkinson’s Disease
Schütz, L., Sixel‐Döring, F., & Hermann, W. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-212749 · Cited by 83
Ghebremedhin, E., Tredici, K. D., Langston, J. W., & Braak, H. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0596-y · Cited by 74
“In the course of the disease, however, the clinical spectrum of PD commonly involves nonmotor symptoms (for review, see [6, 29]), and it has been shown that PD-related neuropathology is not confined to the brain or central nervous system but is distributed throughout the entire nervous system [2, 17].”
BackgroundSwallowing Dysfunctions in Parkinson's Disease
Simons, J. A. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.026 · Cited by 77
Kouchaki, E., Kakhaki, R. D., Tamtaji, O. R., Dadgostar, E., Behnam, M., Nikoueinejad, H., & Akbari, H. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.01.022 · Cited by 74
NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease
Vanle, B., Olcott, W., Jimenez, J. M., Bashmi, L., Danovitch, I., & IsHak, W. W. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0162-2 · Cited by 79
The hidden side of Parkinson’s disease: Studying pain, anxiety and depression in animal models
Faivre, F., Joshi, A., Bézard, E., & Barrot, M. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.10.004 · Cited by 73
Art therapy for Parkinson's disease
Cucca, A., Rocco, A. D., Acosta, I., Beheshti, M., Berberian, M., Bertisch, H. C., Droby, A., Ettinger, T., Hudson, T. E., Inglese, M., et al. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.01.013 · Cited by 77
Altered Resting-State Brain Activity and Connectivity in Depressed Parkinson’s Disease
Hu, X., Song, X., Erfeng, L., Liu, J., Yuan, Y., Liu, W., & Liu, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131133 · Cited by 73
Ma, C., Ouyang, J., Chen, H., & Zhao, X. (2014) · Computational and Mathematical Methods in Medicine · doi:10.1155/2014/985789 · Cited by 73
Roth, B., Studer, U. E., Fowler, C. J., & Kessler, T. M. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.01.049 · Cited by 73
Fifel, K., Vezoli, J., Dzahini, K., Claustrat, B., Leviel, V., Kennedy, H., Procyk, E., Dkhissi‐Benyahya, O., Gronfier, C., & Cooper, H. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086240 · Cited by 78
“insomnia, excessive daytime sleepiness and fragmentation of sleep architecture [1,2].”
BackgroundSUMO ‐regulated mitochondrial function in Parkinson's disease
Souza, A. C. G., Prediger, R. D., & Cimarosti, H. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13599 · Cited by 78
Neurotransmission systems in Parkinson’s disease
Moghaddam, H. S., Zare-Shahabadi, A., Rahmani, F., & Rezaei, N. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0068 · Cited by 78
Improved Spiral Test Using Digitized Graphics Tablet for Monitoring Parkinson’s Disease
Isenkul, M. E., Sakar, B. E., & Kurşun, O. (2014) · doi:10.13140/rg.2.1.1898.6005 · Cited by 75
Nonmotor Symptoms in Amyotrophic Lateral Sclerosis: A Systematic Review
Fang, T., Jozsa, F., & Al‐Chalabi, A. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.04.009 · Cited by 71
Impaired sleep quality and restless legs syndrome in idiopathic focal dystonia: a controlled study
Paus, S., Gross, J., Martina, M.-M., Frank, H., Spottke, A. E., Wabbels, B., Klockgether, T., & Abele, M. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6029-6 · Cited by 72
Angelini, M., Negrotti, A., Marchesi, E., Bonavina, G., & Calzetti, S. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.08.012 · Cited by 72
“This finding has raised the concept that PD by itself could represent a risk or predisposing condition to the development of RLS rather than the opposite, as had been previously hypothesized [15].”
ResultMartínez‐Martín, P., Leentjens, A. F. G., de Pedro-Cuesta, J., Chaudhuri, К. R., Schrag, A. E., & Weintraub, D. A. (2015) · Movement Disorders · doi:10.1002/mds.26522 · Cited by 72
Trichloroethylene, a ubiquitous environmental contaminant in the risk for Parkinson's disease
Miranda, B. R. D., & Greenamyre, J. T. (2020) · Environmental Science Processes & Impacts · doi:10.1039/c9em00578a · Cited by 71
Patel, B., Legacy, J., Wheeler‐Hegland, K., Okun, M. S., & Herndon, N. E. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1769475 · Cited by 71
How COVID-19 will boost remote exercise-based treatment in Parkinson’s disease: a narrative review
Langer, A., Gassner, L., Flotz, A., Hasenauer, S., Gruber, J., Wizany, L., Pokan, R., Maetzler, W., & Zach, H. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00160-3 · Cited by 71
Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease
Madelung, C. F., Meder, D., Fuglsang, S. A., Marques, M. M., Boer, V. O., Madsen, K. H., Petersen, E. T., Hejl, A., Løkkegaard, A., & Siebner, H. R. (2022) · Movement Disorders · doi:10.1002/mds.28945 · Cited by 69
“Patients’ motor and nonmotor symptom severity was assessed in the on state (on their usual dopaminergic treatment) using the Unified Parkinson’s Disease Rating Scale (UPDRS) and the Non-Motor Symptom Scale (NMSS).(27,28) Patients’ blood pressure was measured in the supine position following a 5-minute rest period afte…”
Weerkamp, N. J., Tissingh, G., Poels, P. J. E., Zuidema, S. U., Munneke, M., Koopmans, R. T. C. M., & Bloem, B. R. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12458 · Cited by 71
“Other studies have also consistently shown that NMS has a much greater effect on quality of life than motor problems.(5,6,35) The overall NMS burden is an important determinant of poor quality of life.”
BackgroundResultParkinson’s disease and REM sleep behavior disorder result in increased non-motor symptoms
Neikrug, A. B., Avanzino, J. A., Liu, L., Maglione, J. E., Natarajan, L., Corey‐Bloom, J., Palmer, B. W., Loredo, J. S., & Ancoli‐Israel, S. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2014.04.009 · Cited by 71
Static posturography in aging and Parkinson's disease
Ickenstein, G. W., Ambach, H., Klöditz, A., Koch, H. J., Isenmann, S., Reichmann, H., & Ziemssen, T. (2012) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2012.00020 · Cited by 71
“possible that lesions in non-dopaminergic systems contribute to the pathophysiology of postural instability in PD (Chaudhuri et al., 2006; Truong et al., 2008).”
McFarlane, D. (2007) · Ageing Research Reviews · doi:10.1016/j.arr.2007.02.001 · Cited by 70
Amalric, M., Lopez, S., Goudet, C., Fisone, G., Battaglia, G., Nicoletti, F., Pin, J., & Acher, F. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.026 · Cited by 70
Environment-contact administration of rotenone: A new rodent model of Parkinson’s disease
Liu, Y., Sun, J., Song, L.-K., Li, J., Chu, S., Yuan, Y., & Chen, N. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.058 · Cited by 69
Functional Representation of Olfactory Impairment in Early Alzheimer's Disease
Förster, S., Vaitl, A., Teipel, S. J., Yakushev, I. Y., Mustafa, M., la Fougère, C. J., Rominger, A., Cumming, P. D., Bartenstein, P., Hampel, H. J., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091549 · Cited by 70
“However, the potential of olfactory testing for screening of early AD might be compromised by the occurrence of impaired olfactory performance in other non-AD neurodegenerativediseases [2,3], as well as healthy aging, such that tests of verbal and spatial learning probably remain standard in clinical practice.”
Parkinson Disease: The Relationship Between Non-motor Symptoms and Motor Phenotype
Ba, F., Obaid, M. T., Wieler, M., Camicioli, R. M., & Martin, W. R. W. (2015) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2015.328 · Cited by 70
“These symptoms have been termed NMS by Chaudhuri and others.(1) The NMS Questionnaire (NMS Quest) was developed(2) and validated(3) to screen for the presence of NMS.”
BackgroundSUN, F., KANTHASAMY, A. G., ANANTHARAM, V., & KANTHASAMY, A. G. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.001 · Cited by 69
Perspectives on recent advances in the understanding and treatment of Parkinson's disease
Schapira, A. H., Agid, Y., Barone, P., Jenner, P., Lemke, M. R., Poewe, W., Rascol, O., Reichmann, H., & Tolosa, E. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02793.x · Cited by 69
“genitourinary problems, postural hypotension and constipation) [27].”
Self-citationTranscranial direct current stimulation lessens dual task cost in people with Parkinson’s disease
Swank, C., Mehta, J. A., & Criminger, C. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.05.010 · Cited by 69
Dopamine and reward hypersensitivity in Parkinson’s disease with impulse control disorder
Drew, D. S., Muhammed, K., Baig, F., Kelly, M. J., Saleh, Y., Sarangmat, N., Okai, D., Hu, M., Manohar, S., & Husain, M. (2020) · Brain · doi:10.1093/brain/awaa198 · Cited by 71
Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions?
Logroscino, G., Urso, D., & Savica, R. (2022) · Neuroepidemiology · doi:10.1159/000525639 · Cited by 79
Genetics in Parkinson’s disease, state-of-the-art and future perspectives
Trevisan, L., Gaudio, A., Monfrini, E., Avanzino, L., Fonzo, A. D., & Mandich, P. (2024) · British Medical Bulletin · doi:10.1093/bmb/ldad035 · Cited by 78
Burchill, E., Watson, C. J., Fanshawe, J. B., Badenoch, J., Rengasamy, E. R., Ghanem, D. A., Holle, C., Conti, I., Sadeq, M. A., Saini, A., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100870 · Cited by 72
“10 Some prognostic measures (such as the Non-Motor Symptom Scale and the SF-36 11,12 ) have multiple elements that directly measure psychiatric symptoms, so these were excluded in order to avoid a bias in which associations were in fl ated by a conceptual overlap in the measurement of exposures and…”
BackgroundInfluentialRisk of incident depression in patients with Parkinson disease in the UK
Becker, C., Brobert, G., Johansson, S., Jick, S. S., & Meier, C. R. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03176.x · Cited by 69
“From a public health perspective, it is important to understand the rate of occurrence of this complication to enable clinicians and caregivers to adequately develop strategies addressing the needs of patients with PD [12].”
BackgroundChanges in diagnosis with follow-up in an incident cohort of patients with parkinsonism
Caslake, R., Moore, J. N., Gordon, J. C., Harris, C. E., & Counsell, C. E. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.144501 · Cited by 71
“with a number of non-motor features, including progressive cognitive impairment, neuropsychiatric symptoms, dysautonomia and sleep disturbance.(1) Accurate diagnosis of PD is important both in”
BackgroundObstructive Sleep Apnea and Cognition in Parkinson's disease
Harmell, A. L., Neikrug, A. B., Palmer, B. W., Avanzino, J. A., Liu, L., Maglione, J. E., Natarajan, L., Corey‐Bloom, J., Loredo, J. S., & Ancoli‐Israel, S. (2016) · Sleep Medicine · doi:10.1016/j.sleep.2016.01.001 · Cited by 69
“In PD, sleep disturbances have been found to impair quality of life and increase the level of disability [9].”
BackgroundTessitore, A., Marano, P., Modugno, N., Pontieri, F. E., Tambasco, N., Canesi, M., Latorre, A., Lopiano, L., Sensi, M., Quatrale, R., et al. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8816-9 · Cited by 69
Mishra, A., Singh, S., Tiwari, V., Parul, P., & Shukla, S. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.11.020 · Cited by 71
Dahlberg, L. S., Lungu, O., & Doyon, J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00127 · Cited by 68
Dar, M. N., Akram, M. U., Yuvaraj, R., Khawaja, S. G., & Murugappan, M. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105327 · Cited by 68
Radad, K., Moldzio, R., Krewenka, C., Kranner, B., & Rausch, W. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00036 · Cited by 68
Redefining Non-Motor Symptoms in Parkinson’s Disease
Peña-Zelayeta, L., Delgado-Minjares, K. M., Villegas-Rojas, M. M., León‐Arcia, K., Santiago-Balmaseda, A., Andrade-Guerrero, J., Pérez-Segura, I., Ortega‐Robles, E., Soto-Rojas, L. O., & Arias-Carrión, Ó. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15050172 · Cited by 80
Inpatient Management of Parkinson Disease
Oguh, O., & Videnović, A. (2011) · The Neurohospitalist · doi:10.1177/1941874411427734 · Cited by 68
“Despite its frequent occurrence, nonmotor manifestations are frequently underreported by patients and underdiagnosed by physicians.(54,55) Most common nonmotor manifestations of PD are mood disturbances (depression and anxiety), impaired sleep–wake cycle, autonomic dysfunction (orthostatic hypotension, urinary and sex…”
BackgroundCrosiers, D., Theuns, J., Cras, P. P., & Broeckhoven, C. V. (2011) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2011.07.003 · Cited by 70
“In addition to the motor disturbances PD is characterized by numerous non-motor symptoms (NMS), e.g. cognitive impairment, autonomic dysregulation, sleep problems and neuropsychiatric symptoms (Chaudhuri et al., 2006).”
BackgroundJang, W., Park, J., Shin, K. J., Kim, J., Kim, J. S., Youn, J., Cho, J. W., Oh, E., Ahn, J. Y., Oh, K., et al. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.11.015 · Cited by 68
“In addition to motor function, non-motor symptoms (NMS) are an important aspect of Parkinson's disease (PD), and they are commonly found in PD patients [1].”
BackgroundBloem, B. R., & Stocchi, F. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03532.x · Cited by 68
Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage?
Batla, A., Phé, V., Min, L. D., & Panicker, J. N. (2016) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12374 · Cited by 68
Development of stem cell-based therapy for Parkinson’s disease
Han, F., Baremberg, D., Gao, J., Duan, J., Lu, X., Zhang, N., & Chen, Q. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0039-8 · Cited by 70
“The reliable identification of non-motor symptoms is important as many non-motor symptoms, including depression, cognitive dysfuction, pain, and sleep disorders, precede the motor dysfunctions; not only is management of these symptoms important for quality of life, but early diagnosis of PD could also be key for effec…”
BackgroundMutated ATP10B increases Parkinson’s disease risk by compromising lysosomal glucosylceramide export
Martin, S., Smolders, S., den Haute, C. V., Heeman, B., van Veen, S., Crosiers, D., Beletchi, I., Verstraeten, A., Gossye, H., Gelders, G., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02145-7 · Cited by 67
Song, W., Guo, X., Chen, K., Chen, X., Cao, B., Wei, Q., Huang, R., Zhao, B., Wu, Y., & Shang, H. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.10.005 · Cited by 67
“NMS are often underrecognized and poorly managed in clinical practice [4].”
BackgroundPredicting Parkinson's disease – why, when, and how?
Postuma, R. B., & Montplaisir, J. Y. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70793-x · Cited by 67
“Autonomic dysfunction is experienced by 40–70% of PD patients [12].”
BackgroundInfluentialMglur4-Positive Allosteric Modulation as Potential Treatment for Parkinson’s Disease
Hopkins, C. R., Lindsley, C. W., & Niswender, C. M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.38 · Cited by 67
Nonmotor Symptoms in Genetic Parkinson Disease
Kasten, M., Kertelge, L., Brüggemann, N., van der Vegt, J., Schmidt, A., Tadić, V., Buhmann, C., Steinlechner, S., Behrens, M. I., Ramı́rez, A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.67.6.670 · Cited by 67
Caudal, D., Alvarsson, A., Björklund, A., & Svenningsson, P. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.09.002 · Cited by 73
“Anhedonia, defined as a “markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day”, is considered as one of the core symptoms of depression in PD (Chaudhuri et al., 2006, Aarsland et al., 2011).”
A Review of Scales to Evaluate Sleep Disturbances in Movement Disorders
Kurtis, M. M., Balestrino, R., Rodríguez‐Blázquez, C., Forjaz, M. J., & Martínez‐Martín, P. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00369 · Cited by 67
Alpha-synuclein deregulates the expression of COL4A2 and impairs ER-Golgi function
Paiva, I., Jain, G., Lázaro, D. F., Gotovac, K., Hentrich, T., Kerimoglu, C., Pinho, R., Szegő, É. M., Burkhardt, S., Capece, V., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.001 · Cited by 68
Stacy, M. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0424-5 · Cited by 66
“Given that none of these questionnaires specifically assesses symptoms of wearing-off, new tools are required to detect both the motor and non-motor symptoms of wearing-off (Reichmann et al. 2005; Chaudhuri et al. 2006a, b). The development and validation of wearing-off questionnaires that can assist physicians in ide…”
BackgroundLi, X., Redus, L., Chen, C., Martinez, P. A., Strong, R., Li, S., & O’Connor, J. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071341 · Cited by 67
“motor symptoms associated with PD that can appear years, sometimes decades, before the onset of the motor phenotype [1,2,3].”
BackgroundBerg, J., Roch, M., Altschüler, J., Winter, C., Schwerk, A. M. K., Kurtz, A., & Steiner, B. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9551-y · Cited by 66
“PD however, is more than just a motor disease – non-motor symptoms, such as cognitive decline or depression also significantly contribute to disability [5, 6].”
BackgroundSuzuki, K., Okada, K., Wakuda, T., Shinmura, C., Kameno, Y., Iwata, K., Takahashi, T., Suda, S., Matsuzaki, H., Iwata, Y., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009260 · Cited by 68
Aguirre-Mardones, C., Iranzo, Á., Vilas, D., Serradell, M., Gaig, C., Santamaría, J., & TOLOSA, E. S. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7742-3 · Cited by 65
“This indicates that the neurodegenerative process in PD extends beyond the substantia nigra and dopaminergic deficit [5–9].”
Contributions of the Basal Ganglia to Temporal Processing: Evidence from Parkinson’s Disease
Jones, C. R. G., & Jahanshahi, M. (2013) · Timing & Time Perception · doi:10.1163/22134468-00002009 · Cited by 66
Rizzo, S. J. S., & Crawley, J. N. (2017) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-022516-022754 · Cited by 67
Zhan, Z., Lin, L., Yu, E., Xin, J., Lin, L., Lin, H., Ye, Q., Chen, X., & Pan, X. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12838 · Cited by 66
Molecular landscape of long noncoding RNAs in brain disorders
Yang, S., Lim, K., Kim, S.-H., & Joo, J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00947-5 · Cited by 66
Respiratory disorders of Parkinson’s disease
Aquino, Y. C., Cabral, L. M., Miranda, N. C., Naccarato, M. C., Falquetto, B., Moreira, T. S., & Takakura, A. C. T. (2021) · Journal of Neurophysiology · doi:10.1152/jn.00363.2021 · Cited by 69
Metadata
- Authors
- Chaudhuri, K. R., Healy, D. G., & Schapira, A. H.
- Affiliations
- Guy's and St Thomas' NHS Foundation Trust (GB)
- The Royal Free Hospital (GB)
- ORCID
- Schapira, Anthony HV
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 235-245
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W1982535961
- Cited by
- 2,807
- References
- 140
- Citations by year
- 2026: 184 · 2025: 170 · 2024: 143 · 2023: 159 · 2022: 168 · 2021: 165 · 2020: 197 · 2019: 168 · 2018: 161 · 2017: 174 · 2016: 152 · 2015: 156 · 2014: 130 · 2013: 130 · 2012: 129
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Parkinson's disease, non-motor symptoms, depression, constipation, pain, genitourinary dysfunction, sleep disorders, substantia nigra pars compacta, neurodegeneration, quality of life, disability
- MeSH terms
- Autonomic Nervous System Diseases, Humans, Pain, Parkinson Disease, Psychotic Disorders, Sleep Wake Disorders, Disease Progression, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
